SCHEMBL6294115

SCHEMBL6294115

COC(=O)[C@H](C)N(C(=O)OC(C)(C)C)c1cc(F)cc(F)c1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 1/20 0.39
FPR2 P25090 1/20 0.35
SCN9A Q15858 1/20 0.35
NPSR1 Q6W5P4 2/20 0.33
MEN1 O00255 1/20 0.33
PLA2G1B P04054 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
ATG4B Q9Y4P1 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CA12 O43570 1/20 0.32
CA14 Q9ULX7 1/20 0.32
USP30 Q70CQ3 1/20 0.31
APP P05067 1/20 0.31
BMP1 P13497 1/20 0.30
POLB P06746 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12813777 0.87 ADRB2 (0.39) FPR2SCN9ANPSR1MEN1PLA2G1B
SCHEMBL8909415 0.86 KMT2A (0.40) FPR2SCN9ANPSR1MEN1PLA2G1B
SCHEMBL6299733 0.86 SLC6A3 (0.35) SLC6A3MEN1KMT2AUSP30
SCHEMBL6299731 0.86 SLC6A3 (0.35) SLC6A3MEN1KMT2AUSP30
SCHEMBL8380101 0.80 KMT2A (0.45) NPSR1MEN1PLA2G1BHTTKMT2A
SCHEMBL27631962 0.80 SLC6A3 (0.33) SLC6A3FPR2SCN9ANPSR1MEN1
SCHEMBL6295154 0.79 SLC6A3 (0.34) SLC6A3MEN1KMT2AUSP30
SCHEMBL7479440 0.78 MT-CO2 (0.46) NPSR1MEN1PLA2G1BHTTKMT2A
SCHEMBL7479568 0.78 MT-CO2 (0.46) NPSR1MEN1PLA2G1BHTTKMT2A
SCHEMBL27824592 0.78 HTT (0.35) SLC6A3NPSR1MEN1PLA2G1BHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6962934-B2 Substituted amino carboxamides for the treatment of Alzheimer's disease ELAN PHARMACEUTICALS, INC. (US) 2005-11-08 US disclosed
US-20030166580-A1 Substituted amino carboxamides for the treatment of alzheimer's disease ELAN PHARMACEUTICALS, INC. 2003-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166580-A1 Substituted amino carboxamides for the treatment of alzheimer's disease BACE1, BACE2, APP SLC6A3 3065/4885FPR2 879/4885SCN9A 2359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.